Metabolic Health
Glucose regulation, incretin biology, weight and cardiometabolic risk.
- 11 dossiers
- 1 guide
Dossiers
11 compounds in this area
5-Amino-1MQ
Not a peptide
A small-molecule NNMT inhibitor studied in mouse models of obesity.
AOD-9604
Investigational compound
A growth-hormone fragment developed for obesity, on the premise of fat loss without growth effects.
Cagrilintide
Investigational compound
Long-acting amylin analogue studied for weight management, principally in combination with semaglutide.
Eloralintide
Investigational compound
A long-acting amylin receptor agonist in clinical development for obesity.
GHRP-2
Investigational compound
Non-selective growth-hormone secretagogue. Its best-evidenced human uses are diagnostic testing of pituitary reserve and, separately, stimulation of appetite.
MOTS-c
Mitochondrial peptide
Mitochondrial-derived peptide signalling in metabolic regulation and exercise physiology.
Retatrutide
Investigational compound
Triple GIP, GLP-1 and glucagon receptor agonism in obesity and metabolic disease.
Semaglutide
Approved therapeutic
GLP-1 receptor agonism in type 2 diabetes, weight management and cardiovascular risk.
SLU-PP-332
Not a peptide
A small-molecule ERR agonist described as an exercise mimetic.
Tesamorelin
Approved therapeutic
GHRH analogue studied for visceral adipose reduction in HIV-associated lipodystrophy.
Tirzepatide
Approved therapeutic
Dual GIP and GLP-1 receptor agonism in type 2 diabetes and obesity.